A comparative double blind randomised study of gemfibrozil and lovastatin in hypercholesterolemia

M. R. Adhikari Prabha, J. Kannampilly Johny, B. M. Hegde, Pereira Pratibha, Maya Pai Dungath, Chowta Nityananda

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To evaluate the safety and efficacy of lovastatin in comparison with gemfibrozil in 60 Indian patients with primary hypercholesterolemia (250-350 mg/dL). Methods: After excluding patients with exclusion criteria, 60 adult patients were randomly allocated to the study medication which contained either lovastatin tablets 20 mg or gemfibrozil capsules of 300 mg for 4 weeks and the lipoprotein profile was estimated before and after the treatment. Results: Of the 60 patients, only 44 were available for efficacy analysis, 18 in gemfibrozil group and 26 in lovastatin group and the rest were drop outs. There was a statistically significant reduction in LDL cholesterol from base line value in lovastatin group (32.8%) in comparison with gemfibrozil group (20.35%). Lovastatin was better in raising HDL cholesterol from the base line value (16.3%) in comparison with gemfibrozil (-1.7%). Although there was better reduction in total cholesterol and triglycerides with lovastatin group, this was statistically not significant. Gastrointestinal side effects severe enough to warrant drug withdrawal occurred only in 3.3% (n=1) of lovastatin group as against 33.3% (n=9) of gemfibrozil group. Conclusion: Lovastatin is superior to gemfibrozil in lowering LDL cholesterol and raising HDL cholesterol and it is better tolerated.

Original languageEnglish
Pages (from-to)314-317
Number of pages4
JournalIndian Journal of Pharmacology
Volume29
Issue number5
Publication statusPublished - 01-10-1997
Externally publishedYes

Fingerprint

Gemfibrozil
Lovastatin
Hypercholesterolemia
Double-Blind Method
LDL Cholesterol
HDL Cholesterol
Tablets
Lipoproteins
Capsules
Triglycerides
Cholesterol
Safety

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Adhikari Prabha, M. R., Kannampilly Johny, J., Hegde, B. M., Pratibha, P., Dungath, M. P., & Nityananda, C. (1997). A comparative double blind randomised study of gemfibrozil and lovastatin in hypercholesterolemia. Indian Journal of Pharmacology, 29(5), 314-317.
Adhikari Prabha, M. R. ; Kannampilly Johny, J. ; Hegde, B. M. ; Pratibha, Pereira ; Dungath, Maya Pai ; Nityananda, Chowta. / A comparative double blind randomised study of gemfibrozil and lovastatin in hypercholesterolemia. In: Indian Journal of Pharmacology. 1997 ; Vol. 29, No. 5. pp. 314-317.
@article{0e1324c624774155b7ac4849d7ae6d18,
title = "A comparative double blind randomised study of gemfibrozil and lovastatin in hypercholesterolemia",
abstract = "Objective: To evaluate the safety and efficacy of lovastatin in comparison with gemfibrozil in 60 Indian patients with primary hypercholesterolemia (250-350 mg/dL). Methods: After excluding patients with exclusion criteria, 60 adult patients were randomly allocated to the study medication which contained either lovastatin tablets 20 mg or gemfibrozil capsules of 300 mg for 4 weeks and the lipoprotein profile was estimated before and after the treatment. Results: Of the 60 patients, only 44 were available for efficacy analysis, 18 in gemfibrozil group and 26 in lovastatin group and the rest were drop outs. There was a statistically significant reduction in LDL cholesterol from base line value in lovastatin group (32.8{\%}) in comparison with gemfibrozil group (20.35{\%}). Lovastatin was better in raising HDL cholesterol from the base line value (16.3{\%}) in comparison with gemfibrozil (-1.7{\%}). Although there was better reduction in total cholesterol and triglycerides with lovastatin group, this was statistically not significant. Gastrointestinal side effects severe enough to warrant drug withdrawal occurred only in 3.3{\%} (n=1) of lovastatin group as against 33.3{\%} (n=9) of gemfibrozil group. Conclusion: Lovastatin is superior to gemfibrozil in lowering LDL cholesterol and raising HDL cholesterol and it is better tolerated.",
author = "{Adhikari Prabha}, {M. R.} and {Kannampilly Johny}, J. and Hegde, {B. M.} and Pereira Pratibha and Dungath, {Maya Pai} and Chowta Nityananda",
year = "1997",
month = "10",
day = "1",
language = "English",
volume = "29",
pages = "314--317",
journal = "Indian Journal of Pharmacology",
issn = "0253-7613",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "5",

}

Adhikari Prabha, MR, Kannampilly Johny, J, Hegde, BM, Pratibha, P, Dungath, MP & Nityananda, C 1997, 'A comparative double blind randomised study of gemfibrozil and lovastatin in hypercholesterolemia', Indian Journal of Pharmacology, vol. 29, no. 5, pp. 314-317.

A comparative double blind randomised study of gemfibrozil and lovastatin in hypercholesterolemia. / Adhikari Prabha, M. R.; Kannampilly Johny, J.; Hegde, B. M.; Pratibha, Pereira; Dungath, Maya Pai; Nityananda, Chowta.

In: Indian Journal of Pharmacology, Vol. 29, No. 5, 01.10.1997, p. 314-317.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A comparative double blind randomised study of gemfibrozil and lovastatin in hypercholesterolemia

AU - Adhikari Prabha, M. R.

AU - Kannampilly Johny, J.

AU - Hegde, B. M.

AU - Pratibha, Pereira

AU - Dungath, Maya Pai

AU - Nityananda, Chowta

PY - 1997/10/1

Y1 - 1997/10/1

N2 - Objective: To evaluate the safety and efficacy of lovastatin in comparison with gemfibrozil in 60 Indian patients with primary hypercholesterolemia (250-350 mg/dL). Methods: After excluding patients with exclusion criteria, 60 adult patients were randomly allocated to the study medication which contained either lovastatin tablets 20 mg or gemfibrozil capsules of 300 mg for 4 weeks and the lipoprotein profile was estimated before and after the treatment. Results: Of the 60 patients, only 44 were available for efficacy analysis, 18 in gemfibrozil group and 26 in lovastatin group and the rest were drop outs. There was a statistically significant reduction in LDL cholesterol from base line value in lovastatin group (32.8%) in comparison with gemfibrozil group (20.35%). Lovastatin was better in raising HDL cholesterol from the base line value (16.3%) in comparison with gemfibrozil (-1.7%). Although there was better reduction in total cholesterol and triglycerides with lovastatin group, this was statistically not significant. Gastrointestinal side effects severe enough to warrant drug withdrawal occurred only in 3.3% (n=1) of lovastatin group as against 33.3% (n=9) of gemfibrozil group. Conclusion: Lovastatin is superior to gemfibrozil in lowering LDL cholesterol and raising HDL cholesterol and it is better tolerated.

AB - Objective: To evaluate the safety and efficacy of lovastatin in comparison with gemfibrozil in 60 Indian patients with primary hypercholesterolemia (250-350 mg/dL). Methods: After excluding patients with exclusion criteria, 60 adult patients were randomly allocated to the study medication which contained either lovastatin tablets 20 mg or gemfibrozil capsules of 300 mg for 4 weeks and the lipoprotein profile was estimated before and after the treatment. Results: Of the 60 patients, only 44 were available for efficacy analysis, 18 in gemfibrozil group and 26 in lovastatin group and the rest were drop outs. There was a statistically significant reduction in LDL cholesterol from base line value in lovastatin group (32.8%) in comparison with gemfibrozil group (20.35%). Lovastatin was better in raising HDL cholesterol from the base line value (16.3%) in comparison with gemfibrozil (-1.7%). Although there was better reduction in total cholesterol and triglycerides with lovastatin group, this was statistically not significant. Gastrointestinal side effects severe enough to warrant drug withdrawal occurred only in 3.3% (n=1) of lovastatin group as against 33.3% (n=9) of gemfibrozil group. Conclusion: Lovastatin is superior to gemfibrozil in lowering LDL cholesterol and raising HDL cholesterol and it is better tolerated.

UR - http://www.scopus.com/inward/record.url?scp=9844231487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9844231487&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 314

EP - 317

JO - Indian Journal of Pharmacology

JF - Indian Journal of Pharmacology

SN - 0253-7613

IS - 5

ER -

Adhikari Prabha MR, Kannampilly Johny J, Hegde BM, Pratibha P, Dungath MP, Nityananda C. A comparative double blind randomised study of gemfibrozil and lovastatin in hypercholesterolemia. Indian Journal of Pharmacology. 1997 Oct 1;29(5):314-317.